

# Prof. ŞERİF ŞENTÜRK

## Personal Information

**Office Phone:** [+90 232 412 6514](tel:+902324126514)

**Email:** serif.senturk@deu.edu.tr

**Web:** <https://avesis.deu.edu.tr/serif.senturk>

## International Researcher IDs

ScholarID: -FQI7JcAAAAJ

ORCID: 0000-0003-3963-2294

Publons / Web Of Science ResearcherID: A-1263-2017

ScopusID: 12545373100

Yoksis Researcher ID: 241258

## Education Information

Post Doctorate, Cold Spring Harbor Laboratory, Cancer Center, United States Of America 2010 - 2015

Doctorate, Ihsan Dogramaci Bilkent University, Institute Of Engineering And Natural Sciences, Molecular Biology and Genetics, Turkey 2003 - 2010

Undergraduate, Bogazici University, Faculty Of Arts And Sciences, Department Of Molecular Biology And Genetics, Turkey 1998 - 2003

## Dissertations

Doctorate, Molecular mechanisms of senescence response to transforming growth factor-beta in liver cancer, Ihsan Dogramaci Bilkent University, Institute Of Engineering And Natural Sciences, Molecular Biology and Genetics, 2010

## Research Areas

Molecular Biology and Genetics, Genetic Engineering, Genomics, Molecular Biology of Cancer

## Academic Titles / Tasks

Professor, Dokuz Eylul University, İzmir Uluslararası Biyotıp Ve Genom Enstitüsü, 2023 - Continues

Associate Professor, Dokuz Eylul University, İzmir Uluslararası Biyotıp Ve Genom Enstitüsü, 2015 - 2023

Research Assistant, Cold Spring Harbor Laboratory, Cshl Cancer Center, Signal Transduction, 2010 - 2015

## Academic and Administrative Experience

Assistant Director of the Institute, Dokuz Eylul University, İzmir Uluslararası Biyotıp Ve Genom Enstitüsü, 2022 - Continues

## Supervised Theses

ŞENTÜRK Ş., Investigation of the molecular role of RUVBL1 gene in malignant pleural mesothelioma, Postgraduate, M.ZEYNEP(Student), 2023

ŞENTÜRK Ş., ŞENTÜRK Ş., Co-targeting of EZH2 and retinoic acid signaling in bladder cancer, Doctorate, G.ÖZGÜN(Student), 2023

ŞENTÜRK Ş., The role of trail mediated signals on the proliferation and function of human INKT cells, Doctorate, Z.ÖZGE(Student), 2023

ŞENTÜRK Ş., Identification and functional characterization of essential genes involved in the development of malignant pleural mesothelioma using CRISPR, Doctorate, E.ÇAKIROĞLU(Student), 2023

ŞENTÜRK Ş., ŞENTÜRK Ş., Modelling neuroendocrine differentiation in bladder cancer and analysis phenotypic and molecular effects, Postgraduate, E.BOYVATLI(Student), 2023

## Published journal articles indexed by SCI, SSCI, and AHCI

- I. **Retinoids and EZH2 inhibitors cooperate to orchestrate anti-oncogenic effects on bladder cancer cells**  
Ozgun G., Yaras T., Akman B., Özden-Yılmaz G., Landman N., Karakülah G., van Lohuizen M., Senturk Ş., Erkek-Ozhan S.  
Cancer Gene Therapy, vol.31, no.4, pp.537-551, 2024 (SCI-Expanded)
- II. **Design of Liposome Formulations for CRISPR/Cas9 Enzyme Immobilization: Evaluation of 5-Alpha-Reductase Enzyme Knockout for Androgenic Disorders**  
Şentürk Ş., Akbaba H., Erel Akbaba G., Başpınar Y.  
ACS OMEGA, vol.8, no.48, pp.46101-46112, 2023 (SCI-Expanded)
- III. **Process development for an effective COVID-19 vaccine candidate harboring recombinant SARS-CoV-2 delta plus receptor binding domain produced by *Pichia pastoris***  
Kalyoncu S., Yilmaz S., Kuyucu A. Z., Sayili D., Mert O., Soyturk H., Gullu S., Akinturk H., Citak E., Arslan M., et al.  
SCIENTIFIC REPORTS, vol.13, no.1, 2023 (SCI-Expanded)
- IV. **FLI1 and FRA1 transcription factors drive the transcriptional regulatory networks characterizing muscle invasive bladder cancer**  
Guneri-Sozeri P. Y., Özden-Yılmaz G., Kisim A., Cakiroglu E., Eray A., Uzuner H., Karakülah G., Pesen-Okvur D., Senturk Ş., Erkek-Ozhan S.  
COMMUNICATIONS BIOLOGY, vol.6, no.1, 2023 (SCI-Expanded)
- V. **Wild-type IDH1 Knockout Leads to G0/G1 Arrest, Impairs Cancer Cell Proliferation, Altering Glycolysis, and the TCA Cycle in Colon Cancer**  
Atalay E. B., Senturk Ş., Kayali H.  
BIOCHEMICAL GENETICS, vol.61, no.4, pp.1470-1486, 2023 (SCI-Expanded)
- VI. **MALT1 paracaspase is overexpressed in hepatocellular carcinoma and promotes cancer cell survival and growth**  
Şentürk Ş.  
LIFE SCIENCES, vol.323, 2023 (SCI-Expanded)
- VII. **The paracaspase MALT1 is a downstream target of Smad3 and potentiates the crosstalk between TGF-beta and NF-kB signaling pathways in cancer cells**  
Mazi F. A., Cakiroglu E., Uysal M., Kalyoncu M., Demirci D., Sozeri P. Y. G., Yilmaz G. O., Ozhan S. E., Şentürk Ş.  
CELLULAR SIGNALLING, vol.105, 2023 (SCI-Expanded)
- VIII. **Differential Occupancy and Regulatory Interactions of KDM6A in Bladder Cell Lines**  
Özden-Yılmaz G., Savas B., Bursalı A., Eray A., Arıbaş A., ŞENTÜRK Ş., Karaca E., Karakülah G., Erkek-Ozhan S.  
CELLS, vol.12, no.6, 2023 (SCI-Expanded)
- IX. **Investigating Partners in Crime: Osimertinib Resistance Mechanisms in Non-small Cell Lung Cancer Using Focused CRISPR Screen**  
Dayanc B. U., Eris S., Cakiroglu E., Mazi F. A., COŞKUN BADUR S., Demirci D., KARAKÜLAH G., ŞENTÜRK Ş.  
JOURNAL OF THORACIC ONCOLOGY, no.9, 2022 (SCI-Expanded)

- X. **Genome-wide CRISPR screen identifies BUB1 as a cancer-dependency gene in malignant pleural mesothelioma**  
Cakiroglu E., ŞENTÜRK Ş., KARAKÜLAH G.  
FEBS OPEN BIO, pp.18, 2022 (SCI-Expanded)
- XI. **Engineering and validation of a dual luciferase reporter system for quantitative and systematic assessment of regulatory sequences in Chinese hamster ovary cells.**  
Toktay Y., Dayanc B., Senturk Ş.  
Scientific reports, vol.12, no.1, pp.6050, 2022 (SCI-Expanded)
- XII. **The Bright and the Dark Side of TGF-beta Signaling in Hepatocellular Carcinoma: Mechanisms, Dysregulation, and Therapeutic Implications**  
Gungor M. Z., Uysal M., Şentürk Ş.  
CANCERS, vol.14, no.4, 2022 (SCI-Expanded)
- XIII. **AXL Knock-Out in SNU475 Hepatocellular Carcinoma Cells Provides Evidence for Lethal Effect Associated with G2 Arrest and Polyploidization**  
Batur T., Argundogan A., Keles U., Mutlu Z., Alotaibi H., Senturk Ş., Ozturk M.  
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, vol.22, no.24, 2021 (SCI-Expanded)
- XIV. **Changes in Wnt and TGF-beta Signaling Mediate the Development of Regorafenib Resistance in Hepatocellular Carcinoma Cell Line HuH7**  
Karabicici M., Azbazdar Y., Ozhan G., Şentürk Ş., Firtina Karagonlar Z., Erdal E.  
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, vol.09, 2021 (SCI-Expanded)
- XV. **An epigenetic switch regulates the ontogeny of AXL-positive/EGFR-TKi-resistant cells by modulating miR-335 expression**  
Tepes P. S., Pal D., Lindsted T., Ibarra I., Lujambio A., Sabinina V. J., ŞENTÜRK Ş., Miller M., Korimerla N., Huang J., et al.  
ELIFE, vol.10, 2021 (SCI-Expanded)
- XVI. **Retinoic acid signaling and bladder cancer: Epigenetic deregulation, therapy and beyond**  
Ozgun G., ŞENTÜRK Ş., Erkek-Ozhan S.  
INTERNATIONAL JOURNAL OF CANCER, vol.148, no.10, pp.2364-2374, 2021 (SCI-Expanded)
- XVII. **Identification of Essential Genes in Malignant Pleural Mesothelioma Using Genome-Wide CRISPR/Cas9-Based Negative Selection Screen**  
Cakiroglu E., Coskun O., Karakulah G., Senturk Ş.  
JOURNAL OF THORACIC ONCOLOGY, no.3, 2021 (SCI-Expanded)
- XVIII. **The Jekyll and Hyde of Cellular Senescence in Cancer**  
Demirci D., Dayanc B., Mazi F. A., Şentürk Ş.  
CELLS, vol.10, no.2, 2021 (SCI-Expanded)
- XIX. **Recruitment of solid lipid nanoparticles for the delivery of CRISPR/Cas9: primary evaluation of anticancer gene editing**  
AKBABA H., EREL AKBABA G., ŞENTÜRK Ş.  
NANOMEDICINE, vol.16, no.12, pp.963-978, 2021 (SCI-Expanded)
- XX. **Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1**  
Klionsky D. J., Abdel-Aziz A. K., Abdelfatah S., Abdellatif M., Abdoli A., Abel S., Abeliovich H., Abildgaard M. H., Abudu Y. P., Acevedo-Arozena A., et al.  
Autophagy, vol.17, no.1, pp.1-382, 2021 (SCI-Expanded)
- XXI. **Genomics and Functional Genomics of Malignant Pleural Mesothelioma**  
Cakiroglu E., Şentürk Ş.  
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, vol.21, no.17, 2020 (SCI-Expanded)
- XXII. **Next-Generation Liver Medicine Using Organoid Models**  
Akbari S., Arslan N., Şentürk Ş., Erdal E.  
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, vol.7, 2019 (SCI-Expanded)
- XXIII. **Inducible CRISPR-based Genome Editing for the Characterization of Cancer Genes**  
Sachan N., Miller M., Shirole N. H., ŞENTÜRK Ş., Corbo V., Kinney J. B., Sordella R.

GENOME EDITING AND ENGINEERING: FROM TALENS, ZFNs AND CRISPRs TO MOLECULAR SURGERY, pp.337-357, 2018 (SCI-Expanded)

- XXIV. **Rapid and tunable method to temporally control gene editing based on conditional Cas9 stabilization**  
ŞENTÜRK Ş., Shirole N. H., Nowak D. G., Corbo V., Pal D., Vaughan A., Tuveson D. A., Trotman L. C., Kinney J. B., Sordella R.  
NATURE COMMUNICATIONS, vol.8, pp.1-10, 2017 (SCI-Expanded)
- XXV. **TP53 exon-6 truncating mutations produce separation of function isoforms with pro-tumorigenic functions**  
Shirole N. H., Pal D., Kasthuber E. R., ŞENTÜRK Ş., Boroda J., Pisterzi P., Miller M., Munoz G., Anderlueh M., Ladanyi M., et al.  
ELIFE, vol.5, 2016 (SCI-Expanded)
- XXVI. **MYC Drives Pten/Trp53-Deficient Proliferation and Metastasis due to IL6 Secretion and AKT Suppression via PHLPP2**  
Nowak D. G., Cho H., Herzka T., Watrud K., DeMarco D. V., Wang V. M. Y., ŞENTÜRK Ş., Fellmann C., Ding D., Beinortas T., et al.  
CANCER DISCOVERY, vol.5, no.6, pp.636-651, 2015 (SCI-Expanded)
- XXVII. **p53 Psi is a transcriptionally inactive p53 isoform able to reprogram cells toward a metastatic-like state**  
ŞENTÜRK Ş., Yao Z., Camiolo M., Stiles B., Rathod T., Walsh A. M., Nemajerova A., Lazzara M. J., Aitorki N. K., Krainer A., et al.  
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol.111, no.32, 2014 (SCI-Expanded)
- XXVIII. **Imetelstat (a telomerase antagonist) exerts off-target effects on the cytoskeleton**  
Mender I., ŞENTÜRK Ş., Ozgunes N., Akcali K. C., Kletsas D., Gryaznov S., CAN A., Shay J. W., DİKMEN Z. G.  
INTERNATIONAL JOURNAL OF ONCOLOGY, vol.42, no.5, pp.1709-1715, 2013 (SCI-Expanded)
- XXIX. **Inhibition of Akt signaling in hepatoma cells induces apoptotic cell death independent of Akt activation status**  
Buontempo F., Ersahin T., Missiroli S., ŞENTÜRK Ş., Etro D., Ozturk M., Capitani S., Cetin-Atalay R., Neri M. L.  
INVESTIGATIONAL NEW DRUGS, vol.29, no.6, pp.1303-1313, 2011 (SCI-Expanded)
- XXX. **Dose- and time-dependent expression patterns of zebrafish orthologs of selected E2F target genes in response to serum starvation/replenishment**  
Sucularli C., ŞENTÜRK Ş., Ozturk M., KONU KARAKAYALI Ö.  
MOLECULAR BIOLOGY REPORTS, vol.38, no.6, pp.4111-4123, 2011 (SCI-Expanded)
- XXXI. **Transforming Growth Factor-Beta Induces Senescence in Hepatocellular Carcinoma Cells and Inhibits Tumor Growth**  
ŞENTÜRK Ş., Mumcuoglu M., Gursoy-Yuzugullu O., Cingoz B., Akcali K. C., Ozturk M.  
HEPATOLOGY, vol.52, no.3, pp.966-974, 2010 (SCI-Expanded)
- XXXII. **The Ability to Generate Senescent Progeny as a Mechanism Underlying Breast Cancer Cell Heterogeneity**  
Mumcuoglu M., Bagislar S., Yuzugullu H., Alotaibi H., Şentürk Ş., Telkoparan P., Gur-Dedeoglu B., Cingoz B., Bozkurt B., Tazebay U. H., et al.  
PLOS ONE, vol.5, no.6, 2010 (SCI-Expanded)
- XXXIII. **Senescence and immortality in hepatocellular carcinoma**  
Ozturk M., ARSLAN ERGÜL A., Bagislar S., ŞENTÜRK Ş., Yuzugullu H.  
CANCER LETTERS, vol.286, no.1, pp.103-113, 2009 (SCI-Expanded)
- XXXIV. **Canonical Wnt signaling is antagonized by noncanonical Wnt5a in hepatocellular carcinoma cells**  
Yuzugullu H., Benhaj K., Ozturk N., ŞENTÜRK Ş., Celik E., Toylu A., Tasdemir N., Yilmaz M., Erdal E., Akcali K. C., et al.  
MOLECULAR CANCER, vol.8, 2009 (SCI-Expanded)
- XXXV. **Reprogramming of replicative senescence in hepatocellular carcinoma-derived cells**  
Ozturk N., Erdal E., Mumcuoglu M., Akcali K. C., Yalcin O., ŞENTÜRK Ş., ARSLAN ERGÜL A., Gur B., Yulug I., Cetin-Atalay R., et al.

## Articles Published in Other Journals

- I. **Leveraging Circular Polymerization and Extension Cloning (CPEC) Method for Construction of CRISPR Screening Libraries**  
Dayanç B., ERİŞ S., ŞENTÜRK Ş.  
BIO-PROTOCOL, vol.15, 2024 (ESCI)
- II. **CRISPR-Cas Functional Genetic Screening: Traditional Review**  
GÜLER KARA H., KOSOVA B., DOĞAN E., BOZOK ÇETİNTAŞ V., ŞENTÜRK Ş.  
Türkiye Klinikleri Tıp Bilimleri Dergisi, vol.42, no.4, pp.311-322, 2022 (Scopus)
- III. **Systematic Analysis of Cytostatic TGF-Beta Response in Mesenchymal-Like Hepatocellular Carcinoma Cell Lines**  
Gungor M. Z., Uysal M., Ozturk M., Şentürk Ş.  
JOURNAL OF GASTROINTESTINAL CANCER, vol.52, no.4, pp.1320-1335, 2021 (Peer-Reviewed Journal)
- IV. **Thioredoxin interacting protein promotes invasion in hepatocellular carcinoma**  
Gunes A., Bagirsakci E., İŞCAN E., ÇAKAN AKDOĞAN G., aykutlu u., ŞENTÜRK Ş., ÖZHAN H. G., ERDAL BAĞRIYANIK Ş. E., NART D., YILMAZ BARBET F., et al.  
Oncotarget, vol.9, no.96, 2018 (Scopus)
- V. **A rapid and tunable method to temporally control Cas9 expression enables the identification of essential genes and the interrogation of functional gene interactions in vitro and in vivo**  
ŞENTÜRK Ş., Shirole N., Nowak D., Corbo V., Vaughan A., Tuveson D., Trotman L., Kepecs A., Stegmeier F., Sordella R.  
BioRxiv, 2015 (Non Peer-Reviewed Journal)

## Books & Book Chapters

- I. **Challenges in First-Line Osimertinib Therapy in EGFR-Mutant Non-small Cell Lung Cancer: Acquired Resistance Is the Issue**  
Uluata Dayanç B., Eriş S., Şentürk Ş.  
in: Lung Cancer Diagnosis and Treatment: An Interdisciplinary Approach, Rezaei Nima, Editor, Springer, Londrina, pp.217-247, 2024
- II. **CRISPR/Cas9 Therapy in Cancer Treatment**  
ÇAKIROĞLU E., ŞENTÜRK Ş.  
in: Innovative Approaches in Cancer Diagnosis and Treatment, YAR SAĞLAM ATİYE SEDA, Editor, Türkiye Klinikleri Medical Biology - Special Topics, pp.44-52, 2024
- III. **RUVBL1/2 Complex in Cancer: Emerging Mechanisms and Therapeutic Opportunities**  
AKDEMİR B., Güngör M. Z., ŞENTÜRK Ş.  
in: Interdisciplinary Cancer Research, Rezaei Nima, Editor, Springer, Cham, Londrina, pp.1-24, 2024
- IV. **Structure and Function of the H19 Long Non-coding RNA in Cancer**  
Güngör Y., Gönül C. P., Şentürk Ş.  
in: Interdisciplinary Cancer Research, Nima Rezaei, Editor, Springer, London/Berlin , London, pp.1-27, 2023
- V. **CRISPR/Cas9 Gene Editing in Mammalian Cells Using LentiCRISPRv2/LentiGuide-Puro Vectors**  
Ameen Z. S., Çakiroğlu E., Şentürk Ş., İbrahim A. U., Özsoz M. E. Ş.  
in: CRISPR-Cas Methods, M. Tofazzal Islam, Kutubuddin Ali Molla, Editor, Springer, London/Berlin , New York, pp.281-299, 2021
- VI. **Inducible CRISPR-based Genome Editing for the Characterization of Cancer Genes**  
Sachan N., Miller M., Shirole N., Şentürk Ş., Corbo V., Kinney J., Sordella R.  
in: Genome Editing and Engineering: From TALENs, ZFNs and CRISPRs to Molecular Surgery, Krishnarao Appasani,

## Refereed Congress / Symposium Publications in Proceedings

- I. **Pooled CRISPR Screening Identifies AP-1 Transcription Factor as a Druggable Driver of Osimertinib Resistance in Non-Small Cell Lung Cancer**  
ULUATA DAYANÇ B., ERİŞ S., ÇAKIROĞLU E., Özden Yılmaz G., Gülfirat N. E., Coşkun Ö. Ş., KARAKÜLAH G., ERKEK ÖZHAN S., ŞENTÜRK Ş.  
The 2024 Annual Congress of the European Association for Cancer Research (EACR 2024), Rotterdam, Netherlands, 10 - 13 June 2024, vol.18, pp.224
- II. **Genome-Wide CRISPR Screens: Unveiling BUB1 Kinase as a Druggable Vulnerability in Malignant Pleural Mesothelioma**  
ÇAKIROĞLU E., ERİŞ S., Öz Ö., KARAKÜLAH G., ŞENTÜRK Ş.  
The 2024 Annual Congress of the European Association for Cancer Research (EACR 2024), Rotterdam, Netherlands, 10 - 13 June 2024, vol.18, pp.183-184
- III. **Genome-wide CRISPR Screening Identifies RUVBL1/2 Complex as a Druggable Vulnerability in Bladder Cancer**  
AKDEMİR B., ERİŞ S., Kalyoncu M., ÇAKIROĞLU E., Coşkun Ö. Ş., KARAKÜLAH G., ŞENTÜRK Ş.  
The 2024 Annual Congress of the European Association for Cancer Research (EACR 2024), Rotterdam, Netherlands, 10 - 13 June 2024, vol.18, pp.180-181
- IV. **Escape from TGF- $\beta$ -induced Senescence Promotes Aggressive Cancer Hallmarks in Epithelial Hepatocellular Carcinoma Cells**  
Kalyoncu M., Demirci D., ERİŞ S., Uluata Dayanç B., ÇAKIROĞLU E., BAŞOL M., UYSAL M., ÇAKAN AKDOĞAN G., KARAKÜLAH G., ŞENTÜRK Ş.  
The 2024 Annual Congress of the European Association for Cancer Research (EACR 2024), Rotterdam, Netherlands, 10 - 13 June 2024, vol.18, pp.347-348
- V. **A molecular portrait of retinoids and EZH2 inhibitors cooperation to orchestrate cytotoxic effects on bladder cancer cells**  
Özgün G., Yaraş T., Landman N., KARAKÜLAH G., van Lohuizen M., ŞENTÜRK Ş., ERKEK ÖZHAN S.  
The 47th FEBS Congress, 8 - 12 July 2023, vol.13
- VI. **The Molecular Role of RUVBL1 Gene on Cancer Cell Phenotypes in Malignant Pleural Mesothelioma**  
Güngör M. Z., Çakıroğlu E., Akdemir B., Şentürk Ş.  
The International Biochemistry Congress & 33rd National Biochemistry Congress, İzmir, Turkey, 26 - 30 October 2022
- VII. **ATG9A Gene is Required for the Survival of Malignant Pleural Mesothelioma Cells**  
Uysal M., Çakıroğlu E., Tutcu Ö., Mutlu Ö., Şentürk Ş.  
The International Biochemistry Congress & 33rd National Biochemistry Congress, İzmir, Turkey, 26 - 30 October 2022, pp.1-5
- VIII. **Investigating Partners in Crime: Osimertinib Resistance Mechanisms in Non-small Cell Lung Cancer Using Focused CRISPR Screen**  
Dayanç B., Eriş S., Çakıroğlu E., Mazı F. A., Coşkun Ö. Ş., Demirci D., Karakülah G., Şentürk Ş.  
IASLC 2022 WCLC World Conference on Lung Cancer, Vienna, Austria, 6 - 09 August 2022, vol.17, pp.407
- IX. **Genome-wide CRISPR screen identifies BUB1 as a cancer-dependency gene in malignant pleural mesothelioma**  
Çakıroğlu E., Şentürk Ş., Karakülah G.  
IUBMB-FEBS-PABMB 2022 Congress, Lisbon, Portugal, 9 - 14 July 2022, vol.12, pp.18
- X. **AXL is essential for survival of mesenchymal-like HCC cells**  
Batur T., Argundogan A., Mutlu Z., KELEŞ U., ALOTAİBİ H., ŞENTÜRK Ş., ÖZTÜRK M.  
8th International Congress of the Molecular Biology Association of Turkey, İstanbul, Turkey, 9 - 12 June 2022
- XI. **The Role of Autophagy on Differentiation of Corneal Endothelial Cells from hiPSCs**

KOÇAK G., Cakiroglu E., YILDIRIM C. A., ŞENTÜRK Ş., GÜVEN S.

8th International Congress of the Molecular Biology Association of Turkey, İstanbul, Turkey, 9 - 12 June 2022

- XII. **Targeted delivery of CRISPR/Cas9 plasmid system for cancer immunotherapy approaches**  
AKBABA H., Özder M., EREL AKBABA G., ŞENTÜRK Ş.  
13th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, Amsterdam, Netherlands, 28 - 31 March 2022
- XIII. **CRISPR-CAS9 Teknolojisi ile in vitro F8 Geninin Fonksiyonunun Bozulmasının Sağlanması**  
Shekari M., GÜNDÜZ C., ATİK T., YILMAZ SÜSLÜER S., ŞENTÜRK Ş., IŞIK E., ÖZKINAY F. F.  
8. Hemofili Vakaları Eğitim Sempozyumu, 18 - 20 February 2022
- XIV. **Küçük Hücreli Dışı Akciğer Kanseri Genetik Olmayan Osimertinib Direnç Mekanizmalarının CRISPR Tarama Aracılı Araştırılması**  
Uluata Dayanç B., Eriş S., Çakıroğlu E., Mazı F. A., Coşkun Ö. Ş., Demirci D., KARAKÜLAH G., ŞENTÜRK Ş.  
XVII. Tıbbi Biyoloji ve Genetik Kongresi, İzmir, Turkey, 28 - 31 October 2021
- XV. **Generation of R132H point mutation by CRISPR/Cas9 method in colorectal cancer cell line**  
BULUT ATALAY E., ŞENTÜRK Ş., AYAR KAYALI H.  
3. Uluslararası Kanser ve İyon Kanalları Kongresi (CANCERION-2021), 16 September 2021
- XVI. **Generation of R132H point mutation by CRISPR/Cas9 method in colon cancer cell line**  
BULUT ATALAY E., ŞENTÜRK Ş., AYAR KAYALI H.  
3. Uluslararası Kanser ve İyon Kanalları Kongresi, İstanbul, Turkey, 16 - 18 September 2021
- XVII. **Generation of cell models using CRISPR/Cas9-based gene therapy to study molecular functions of IDH in colorectal cancer**  
BULUT ATALAY E., Çakıroğlu E., ŞENTÜRK Ş., AYAR KAYALI H.  
BioTürkiye Uluslararası Biyoteknoloji Kongresi, İstanbul, Turkey, 9 - 11 September 2021
- XVIII. **Revealing the Role of Retinoids On the Phenotypic and Epigenetic Landscape of Bladder Cancer Cells**  
Özgün G., ŞENTÜRK Ş., ERKEK ÖZHAN S.  
6. Uluslararası Tıp ve Sağlık Bilimleri Araştırmaları Kongresi, Ankara, Turkey, 10 - 11 April 2021
- XIX. **P62.02 Identification of Essential Genes in Malignant Pleural Mesothelioma Using Genome-Wide CRISPR/Cas9-Based Negative Selection Screen**  
Çakıroğlu E., Coşkun Ö. Ş., KARAKÜLAH G., ŞENTÜRK Ş.  
IASLC 2020 World Conference on Lung Cancer, Singapore, 28 - 31 January 2021, vol.16, pp.548
- XX. **Gen Düzeltme ve CRISPR**  
ŞENTÜRK Ş.  
Türk Toraks Derneği 23. Yıllık Kongresi, Turkey, 15 - 18 October 2020
- XXI. **A Novel Concept for Immune Checkpoint Gene Knockout Via Lipid Based Non-Viral Delivery Systems**  
AKBABA H., Özder M., EREL AKBABA G., ŞENTÜRK Ş.  
Bio Turkey International Biotechnology Congress, İstanbul, Turkey, 5 - 07 March 2020
- XXII. **Genç Araştırmacılar İçin Fırsatlar**  
ŞENTÜRK Ş.  
BioTürkiye - Uluslararası Biyoteknoloji Kongresi, İstanbul, Turkey, 5 - 07 March 2020
- XXIII. **CRISPR-Cas9 Genom Düzenleme**  
ŞENTÜRK Ş.  
22. EGE Onkoloji Günleri-Onkolojide Yeni Tedavi Arayışları Sempozyumu, Turkey, 26 - 28 February 2020
- XXIV. **Genome-wide CRISPR-Cas9 screening for the identification of cancer essential genes in malignant pleural mesothelioma**  
Çakıroğlu E., Coşkun Ö. Ş., ŞENTÜRK Ş.  
27th Balkan Clinical Laboratory Federation Congress and 30th National Biochemistry Congress, Turkey, 27 - 31 October 2019, vol.44
- XXV. **HEPATOSELÜLER KARSİNOMADA YENİ YAKLAŞIM: POTANSİYEL İLAÇ HEDEFİ OLARAK AXL RESEPTÖRÜ**  
Batur T., KELEŞ U., İŞCAN E., Öz Ö., ŞENTÜRK Ş., ÇAKAN AKDOĞAN G., mutlu z., ÖZTÜRK M.  
Onkolojide İz Bırakanlar, Antalya, Turkey, 14 - 17 November 2019

- XXVI. **Malign plevral mezotelyoma tümörigenez mekanizmalarının CRISPR-Cas9 tarama ile araştırılması**  
Çakıroğlu E., Coşkun Ö. Ş., Kurden Pekmezci A., ŞENTÜRK Ş.  
Onkolojide İz Bırakanlar Zirvesi, Antalya, Turkey, 14 - 17 November 2019
- XXVII. **HEPATOSELLÜLER KARSİNOMDA TGF-B YANITININ HÜCRESEL MEKANİZMALARININ ARAŞTIRILMASI**  
DEMİRCİ D., ECE Ç., BENGİSU U. D., KARAKÜLAH G., ÖZTÜRK M., ŞENTÜRK Ş.  
ONKOLOJİDE İZ BIRAKANLAR ZİRVESİ, Turkey, 14 - 17 November 2019
- XXVIII. **TGF-β'ya bağlı kanser hücre sekretomunun regülasyonunda Malt1'in rolü**  
MAZI F. A., Çakıroğlu E., Kurden Pekmezci A., Demirci D., ŞENTÜRK Ş.  
Onkolojide İz Bırakanlar Zirvesi, Antalya, Turkey, 14 - 17 November 2019
- XXIX. **İnvaziv olan ve invaziv olmayan mesane kanseri hücre hatlarını karakterize eden transkripsiyonel düzenleyici ağların tanımlanması**  
Güneri P. Y., Özden Yılmaz G., Eray A., ATABEY S. N., ŞENTÜRK Ş., Erkek S.  
Onkolojide İz Bırakanlar Zirvesi, Turkey, 14 - 17 November 2019
- XXX. **Hepatoselüler karsinom hücre hatlarında Malt1 tükenmesinin büyüme baskılayıcı etkilerinin araştırılması**  
Kurden Pekmezci A., Coşkun Ö. Ş., Çakıroğlu E., Demirci D., ŞENTÜRK Ş.  
Onkolojide İz Bırakanlar Zirvesi, Antalya, Turkey, 14 - 17 November 2019
- XXXI. **Hepatoselüler Karsinoma'da AXL'in rolü**  
Batur T., KELEŞ U., ŞENTÜRK Ş., ÇAKAN AKDOĞAN G., mutlu Z., İŞCAN E., ÖZTÜRK M.  
16.Tıbbi Biyoloji ve Genetik Kongresi, 27 - 30 October 2019
- XXXII. **Identification of transcriptional regulatory networks characterizing invasive and non-invasive bladder cancer cell lines.**  
Güneri P. Y., Özden Yılmaz G., Eray A., ATABEY S. N., ŞENTÜRK Ş., Erkek S.  
The International Symposium on Health Informatics and Bioinformatics, 17 - 19 October 2019
- XXXIII. **Identification of transcriptional regulatory networks characterizing invasive and non-invasive bladder cancer cell lines**  
Güneri P. Y., Yılmaz G. Ö., Eray A., ATABEY S. N., ŞENTÜRK Ş., Erkek S.  
17th Meeting of the International Bladder Cancer Network, 3 - 05 October 2019
- XXXIV. **Malt1 Paracaspase Inhibition Reduces Hepatocellular Carcinoma Cell Survival**  
Kurden Pekmezci A., Coşkun Ö. Ş., Çakıroğlu E., Demirci D., ŞENTÜRK Ş.  
1st INTERNATIONAL MULTIDISCIPLINARY CANCER RESEARCH CONGRESS, 18 - 22 September 2019
- XXXV. **Investigation of cellular mechanisms of TGF-beta resistance in hepatocellular carcinoma**  
Demirci D., Çakıroğlu E., KARAKÜLAH G., ÖZTÜRK M., ŞENTÜRK Ş.  
3. Çukurova Hepatoselüler Karsinoma Kongresi, Adana, Turkey, 21 - 23 February 2019
- XXXVI. **Investigation of the role of Malt1 Paracaspase in Hepatocellular Carcinoma Cell Survival**  
Kurden Pekmezci A., Coşkun Ö. Ş., Çakıroğlu E., ŞENTÜRK Ş.  
3. Çukurova Hepatoselüler Karsinoma Kongresi, Adana, Turkey, 21 - 23 February 2019
- XXXVII. **Kanser Esansiyel Genlerin Tüm Genom CRISPR-Cas9 Taramalarıyla Araştırılması**  
ŞENTÜRK Ş.  
İmmünolojide Moleküller Sempozyumu, Turkey, 18 - 21 October 2018
- XXXVIII. **Investigation of the Cellular Mechanisms of TGF-β-induced Senescence-Resistance in Hepatocellular Carcinoma**  
Demirci D., Çakıroğlu E., Bingöl B., KARAKÜLAH G., ÖZTÜRK M., ŞENTÜRK Ş.  
6th International Congress of the Molecular Biology Association of Turkey, 5 - 08 September 2018
- XXXIX. **Systematic Comparison of Constitutive Promoters in Chinese Hamster Ovary Cells**  
Toktay Y., Zeybek Kuyucu A., Gürkan Y., ŞENTÜRK Ş.  
6th International Congress of the Molecular Biology Association of Turkey, 5 - 08 September 2018
- XL. **The Role of Malt1 Paracaspase in Hepatocellular Carcinoma**  
Kurden Pekmezci A., Çakıroğlu E., ŞENTÜRK Ş.  
6th International Congress of the Molecular Biology Association of Turkey, 5 - 08 September 2018
- XLI. **Engineering and Functional Validation of Clonal Cell Lines with Stable Cas9 Expression for Genome-**



## **Wide CRISPR Screen in Malignant Pleural Mesothelioma**

Çakroğlu E., Dumral Ö., Coşkun Ö. Ş., ŞENTÜRK Ş.

6th International Congress of the Molecular Biology Association of Turkey, 5 - 08 September 2018

- XLII. **AXL as a Potential Target in Liver Cancer**  
Batur T., KELEŞ U., İŞCAN E., ŞENTÜRK Ş., ÖZTÜRK M.  
6th International Congress of the Molecular Biology Association of Turkey, 5 - 08 September 2018
- XLIII. **THE NEW FRONTIER OF GENOME ENGINEERING: THE CRISPR/CAS9 SYSTEM**  
ŞENTÜRK Ş.  
The Second International Biomedical Engineering Congress, 24 - 27 May 2018
- XLIV. **Genom Mühendisliği ve CRISPR-Cas Devrimi**  
ŞENTÜRK Ş.  
14. Ulusal Histoloji ve Embriyoloji Kongresi, Turkey, 10 - 13 May 2018
- XLV. **TXNIP'xxin HCC gelişimi ve ilerleyişindeki rolü**  
Güneş A., İŞCAN E., Bağırsakçı E., ÇAKAN AKDOĞAN G., aykutlu u., ŞENTÜRK Ş., ÖZHAN H. G., ERDAL BAĞRIYANIK Ş., E., NART D., Yılmaz Y., et al.  
XV.Ulusal Tıbbi Biyoloji ve Genetik Kongresi, Turkey, 26 - 29 October 2017
- XLVI. **Biyobelirteçler ve CRISPR**  
ŞENTÜRK Ş.  
II. Türkiye in vitro Diyagnostik (IVD) Sempozyumu, Turkey, 10 - 12 May 2017
- XLVII. **CRISPR/Cas9 İşlevsel Genomik Tarama ve Rekabet Tayini ile Kanser Esansiyel Genlerin Keşfi ve in Vitro Karakterizasyonu**  
ŞENTÜRK Ş.  
1. Çukurova Hepatoselüler Karsinoma Sempozyumu, Turkey, 10 - 12 February 2017
- XLVIII. **In Vitro and In Vivo Characterization Of Cell Survival Genes Using Destabilized Cas9**  
ŞENTÜRK Ş.  
1st International Cell Death Research Congress, İzmir, Turkey, 4 - 07 May 2016
- XLIX. **Role of MCP1 in Tumor Microenvironment**  
Sachan N., ŞENTÜRK Ş., Raffaella S.  
2016 CSHL Annual Symposium, 21 - 22 November 2016
- L. **TP53 Truncating Alleles in Tumor Progression**  
Shirole N., Pal D., ŞENTÜRK Ş., Sordella R.  
CSHL Annual Symposium, 21 - 22 November 2016
- LI. **Truncating Alleles in TP53 Produce Separation of Function Mutants That Actively Promote Tumorigenesis**  
Shirole N., Pal D., Kasthuber E., ŞENTÜRK Ş., Pisterzi P., Boroda J., Munoz G., Lowe S., Sordella R.  
81st Cold Spring Harbor Laboratory Symposium on Quantitative Biology, 1 - 05 June 2016
- LII. **A rapid and tunable method to temporally control Cas9 expression enables the characterization of essential genes and the interrogation of functional gene interactions in vitro and in vivo**  
ŞENTÜRK Ş., Shirole N., Nowak D. G., Corbo V., Tuveson D. A., Trotman L. C., Sordella R.  
Genome Engineering: The CRISPR/CAS Revolution, 24 - 27 September 2015
- LIII. **Myc drives Pten p53 deficient proliferation and metastasis due to Il6 secretion and Akt suppression via Phlpp2**  
Nowak D. G., Cho H., Herzka T., Wang V. M., ŞENTÜRK Ş., DeMarco D. V., Ding D., Fellmann C., Beinortas T., Kleinman D., et al.  
AACR Annual Meeting, 18 - 22 April 2015
- LIV. **Myc drives Pten/ p53-deficient proliferation and metastasis due to Il6-secretion and Akt-suppression via Phlpp2**  
Nowak D. G., Cho H., Herzka T., Wang V. M. Y., ŞENTÜRK Ş., DeMarco D. V., Ding D., Fellmann C., Beinortas T., Kleinman D., et al.  
106th Annual Meeting of the American-Association-for-Cancer-Research (AACR), Pennsylvania, United States Of America, 18 - 22 April 2015, vol.75

- LVI. Does Akt Inactivation promote metastasis of PTEN mutant cancer**  
Dawid N., Cho H., Herzka T., Wang V., ŞENTÜRK Ş., Demarco D., Christoff F., Wartrud K., Sordella R., Trotman L.  
Biology of Cancer: Microenvironment, Metastasis & Therapeutics, 12 - 16 May 2015
- LVI. Functional characterization of genomic abnormalities that cooperate with EGFR and K Ras oncogenic mutations in lung cancer**  
ŞENTÜRK Ş., Shirole N., Camiolo M., Van Aelst L., Lowe S., Sander C., Ladanyi M., Mittal V., Sordella R.  
Starr Cancer Consortium, 11 - 12 May 2015
- LVII. Substrate specificity of receptor tyrosine kinases is critical for selective signaling and addiction**  
PINEDA M., YAO Z., PUZIS L., ŞENTÜRK Ş., SORDELLA R.  
Protein Phosphorylation, Cellular Plasticity and Signaling Rewiring, FASEB Meeting, 20 - 25 July 2014
- LVIII. Substrate specificity of receptor tyrosine kinases is critical for selective signaling**  
PINEDA M., YAO Z., LINDSTED T., ŞENTÜRK Ş., SORDELLA R.  
Mechanisms & Models of Cancer Meeting, CSHL, 14 - 18 August 2012
- LIX. p53 is a neomorphic p53 isoform that reprograms cells towards the acquisition of metastatic features despite lacking transcriptional activity**  
CAMIOLO M., YAO Z., ŞENTÜRK Ş., LINDSTED T., KRAÏNER A., LOWE S., SORDELLA R.  
Mechanisms & Models of Cancer Meeting, CSHL, 14 August - 18 April 2012
- LX. SOCS2 leads to EGFR TKi resistance in lung cancer by activating IL 6 mediated signaling**  
ŞENTÜRK Ş., TAŞ İ., YAO Z., FENOGLİO S., SORDELLA R.  
Mechanisms & Models of Cancer Meeting, CSHL, 14 - 18 August 2012
- LXI. The Effects of Telomerase Inhibitor GRN163L Imetelstat On Cell Cytoskeleton and Cell Cycle**  
MENDER İ., ŞENTÜRK Ş., GRYAZNOV S., ÖZGÜNEŞ N., CAN A., DİKMEN Z. G.  
21st Biochemistry Congress, İstanbul, Turkey, 28 - 31 October 2009
- LXII. TGF-BETA SIGNALING IS FUNCTIONAL, BUT ITS SENESENCE RESPONSE IS DEFECTIVE IN POORLY DIFFERENTIATED HEPATOCELLULAR CARCINOMA CELL LINES**  
ŞENTÜRK Ş., Ozturk M.  
60th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, Massachusetts, United States Of America, 30 October - 03 November 2009, vol.50
- LXIII. Effect of Akt pathway inhibitors in HCC a novel target for treatment**  
ERŞAHİN T., BUONTEMPO F., ŞENTÜRK Ş., NERİ L., ATALAY R.  
3rd ILCA Annual Conference, Milan, Italy, 4 - 06 September 2009
- LXIV. The Effects of Telomerase Inhibitor GRN163L on Different Cell Lines**  
MENDER İ., ŞENTÜRK Ş., DİKMEN Z. G., GRYAZNOV S., CAN A., ÖZGÜNEŞ N.  
2nd FEBS Advanced Lecture Course on Matrix Pathobiology, Patras, Greece, 11 - 16 July 2009
- LXV. Downregulation and the anti growth effect of Zeb2 in hepatocellular carcinoma**  
ERGÜL A., BAĞIŞLAR S., ÖZTÜRK N., ŞENTÜRK Ş., YÜZÜGÜLLÜ H., BOZDOĞAN Ö., MIZRAK D., SAYAN E., TULCHINSKY E., ÖZTÜRK M.  
Joint 4th EORTC Annual Meeting & 1st International Multidisciplinary Cancer Research Congress, 21 - 24 May 2009
- LXVI. TGF beta induces senescence in epithelial like hepatocellular carcinoma cells**  
ŞENTÜRK Ş., ÖZTÜRK M.  
Joint 4th EORTC Annual Meeting & 1st International Multidisciplinary Cancer Research Congress, 21 - 24 May 2009
- LXVII. Molecular Mechanisms of TGF beta induced senescence in hepatocellular carcinoma**  
ŞENTÜRK Ş., ÖZTÜRK M.  
20. ULUSAL BİYOKİMYA KONGRESİ, Turkey, 29 October - 01 November 2008
- LXVIII. TGF beta induces p53 Rb independent but oxidative stress dependent cellular senescence in hepatocellular carcinoma cells**  
ŞENTÜRK Ş., ERGÜL A., AKKIZ H., ÖZTÜRK M.  
ILCA Meeting, 5 - 07 October 2007
- LXIX. SMAD interacting protein 1 SIP 1 acts as a negative regulator of growth in hepatocellular carcinoma cells**  
ERGÜL A., BAĞIŞLAR S., ÖZTÜRK N., ŞENTÜRK Ş., ÖZTÜRK M.

ILCA MEETING, 5 - 07 October 2007

- LXX. **Induction of senescence as a potential therapeutic strategy in hepatocellular carcinoma**  
ÖZTÜRK M., BAĞIŞLAR S., ŞENTÜRK Ş., ARSLAN ERGÜL A., ÖZTÜRK N.  
International Meeting on Translational Worldwide Perspective for Liver Cancer, 9 - 10 July 2007
- LXXI. **Role of TGF beta and ROS signaling pathways in hepatocellular senescence**  
ŞENTÜRK Ş., ERGÜL A., ÖZTÜRK N., AKKIZ H., ÖZTÜRK M.  
II. International Congress of Molecular Medicine, Istanbul, 24 - 28 March 2007
- LXXII. **Role of SMAD interacting protein 1 in reprogramming of replicative senescence**  
ERGÜL A., BAĞIŞLAR S., ÖZTÜRK N., ŞENTÜRK Ş., LAÇIN E., ÖZTÜRK M.  
II. International Congress of Molecular Medicine, 24 - 28 March 2007
- LXXIII. **TGF beta Signaling Pathway in Hepatocellular Senescence**  
ŞENTÜRK Ş., ÖZTÜRK M.  
6th FEBS Young Scientists Forum, 22 - 24 June 2006
- LXXIV. **Induction of replicative senescence in hepatocellular carcinoma cells**  
Ozturk N., Erdal E., Mumcuoglu M., Akcali K. C., YALÇIN Ö. T., ŞENTÜRK Ş., Arslan-Ergul A., Tez M., Ozturk M.  
31st Congress of the Federation-of-European-Biochemical-Societies (FEBS), İstanbul, Turkey, 24 - 29 June 2006,  
vol.273, pp.224-225
- LXXV. **Role of TGF-beta signaling in hepatocellular senescence**  
ŞENTÜRK Ş., Arslan-Ergul A., Ozturk N., Akkiz H., Ozturk M.  
31st Congress of the Federation-of-European-Biochemical-Societies (FEBS), İstanbul, Turkey, 24 - 29 June 2006,  
vol.273, pp.225
- LXXVI. **Characterization of TGF beta induced Early Senescence in Hepatocellular Carcinoma Cell Lines**  
ŞENTÜRK Ş., ÖZTÜRK M.  
ICGEB Workshop Emerging Topics in Human Functional Genomics and Proteomics, 26 - 31 March 2006

## **Non Academic Experience**

Cold Spring Harbor Laboratory